Liquid-based cytology
This article was originally published in The Gray Sheet
Executive Summary
Technology is recommended by NICE in 1LBC guidance as the primary means of processing Pap smear samples in the UK's cervical screening program. The UK body released a final appraisal on the procedure in August (2"The Gray Sheet" Aug. 18, 2003, In Brief)...
You may also be interested in...
NICE endorses liquid-based cytology
National Institute for Clinical Excellence final appraisal determination issued Aug. 15 recommends using the technology as the primary means of processing samples in the UK's cervical screening program. Implementation of the policy - representing 4 mil. annual tests - should take about three to five years. The decision was applauded by LBC stakeholders Cytyc (ThinPrep) and TriPath (SurePath). NICE issued a preliminary recommendation in April (1"The Gray Sheet" April 21, 2003, p. 6)...
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
Pair Of Deaths Linked To Recalled Vyaire Medical Respiratory Devices
The US FDA has labelled a recall of more than 6 million Airlife respiratory support devices class I. The recall covers devices manufactured in 2017 or earlier that can fail to provide adequate ventilation.